Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...

Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024). LITESPARK-005, KEYNOTE-564, TIVO-3, CLEAR, CHECKMATE-9ER, ...

This observational study investigated the effects of patient factors and quality of life on ECOG-PS scores and interobserver agreement in hospitalized oncology patients.

Eastern Cooperative Oncology Group Performance Status (ECOG-PS) is commonly used in cancer trials to select a study population with good performance, but ECOG-PS is rarely available in health-care ...

Individuals diagnosed with advanced cancer often experience stress and depression, factors linked to worse survival. Curability belief—defined as the hope and expectation of cure through treatment, ...

Incorporating ICIs into platinum-doublet regimens improved OS and ORR in ES-SCLC patients with ECOG PS 2 to 3, but not in those with ECOG PS 0 to 1. The study found manageable adverse reactions, with ...

Tumor-Targeted IL-12 (PDS01ADC) With Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Nonrandomized Phase II Trial Patients with mCRC exposed to FTD-TPI + ...